以胆汁酸和脂毒性为靶点治疗非酒精性脂肪性肝炎 - Suppr

Suppr

超能文献

Targeting bile acids and lipotoxicity for NASH treatment.

作者信息

Chiang John Y L

机构信息

Northeast Ohio Medical University Rootstown OH.

出版信息

Hepatol Commun. 2017 Dec 4;1(10):1002-1004. doi: 10.1002/hep4.1127. eCollection 2017 Dec.

DOI:10.1002/hep4.1127

PMID:29404437

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5721403/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e5/5721403/5ebb022d5def/HEP4-1-1002-g001.jpg

相似文献

Targeting bile acids and lipotoxicity for NASH treatment.以胆汁酸和脂毒性为靶点治疗非酒精性脂肪性肝炎

Hepatol Commun. 2017 Dec 4;1(10):1002-1004. doi: 10.1002/hep4.1127. eCollection 2017 Dec.

Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats.腺苷 A(2a)受体刺激可预防大鼠肝细胞脂肪毒性和非酒精性脂肪性肝炎（NASH）。

Clin Sci (Lond). 2012 Sep;123(5):323-32. doi: 10.1042/CS20110504.

Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.非酒精性脂肪性肝炎的发病机制：营养过剩的代谢并发症如何导致脂毒性和促炎脂肪性肝病。

Adv Exp Med Biol. 2018;1061:19-44. doi: 10.1007/978-981-10-8684-7_3.

Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis.油酸可保护肝细胞及非酒精性脂肪性肝炎大鼠中饱和脂肪酸介导的脂毒性。

Life Sci. 2018 Jun 15;203:291-304. doi: 10.1016/j.lfs.2018.04.022. Epub 2018 Apr 27.

Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎患者胆汁酸代谢组的改变

Dig Dis Sci. 2015 Nov;60(11):3318-28. doi: 10.1007/s10620-015-3776-8. Epub 2015 Jul 3.

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.2型糖尿病合并非酒精性脂肪性肝病患者的治疗：当前方法与未来方向

Diabetologia. 2016 Jun;59(6):1112-20. doi: 10.1007/s00125-016-3952-1. Epub 2016 Apr 21.

Pathogenesis of Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎的发病机制

Gastroenterology. 2016 Jun;150(8):1769-77. doi: 10.1053/j.gastro.2016.02.066. Epub 2016 Feb 27.

Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.游离脂肪酸抑制小异二聚体伴侣（SHP）的激活，脂联素可拮抗胆汁酸诱导的非酒精性脂肪性肝炎超肥胖患者的肝损伤。

Hepatology. 2013 Apr;57(4):1394-406. doi: 10.1002/hep.26225.

The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.选择性过氧化物酶体增殖物激活受体δ激动剂塞拉德尔帕通过消除糖尿病肥胖小鼠的脂毒性来逆转非酒精性脂肪性肝炎病理。

Hepatol Commun. 2017 Jul 31;1(7):663-674. doi: 10.1002/hep4.1072. eCollection 2017 Sep.

Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice.工程化的成纤维细胞生长因子19（FGF19）可消除胆汁酸毒性和脂毒性，从而使小鼠的脂肪性肝炎和肝纤维化得到缓解。

Hepatol Commun. 2017 Oct 16;1(10):1024-1042. doi: 10.1002/hep4.1108. eCollection 2017 Dec.

引用本文的文献

Spaceflight alters host-gut microbiota interactions.太空飞行改变了宿主-肠道微生物群的相互作用。

NPJ Biofilms Microbiomes. 2024 Aug 29;10(1):71. doi: 10.1038/s41522-024-00545-1.

Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD).过氧化物酶体增殖物激活受体α（PPARα）功能丧失会促进脂质稳态的表观遗传失调，从而在代谢功能障碍相关脂肪性肝病（MASLD）中引发铁死亡和焦亡脂毒性。

Front Mol Med. 2024 Jan 8;3:1283170. doi: 10.3389/fmmed.2023.1283170. eCollection 2023.

LPJZ-658 Improves Non-Alcoholic Steatohepatitis by Modulating Bile Acid Metabolism and Gut Microbiota in Mice.LPJZ-658 通过调节胆汁酸代谢和肠道微生物群改善小鼠非酒精性脂肪性肝炎。

Int J Mol Sci. 2023 Sep 12;24(18):13997. doi: 10.3390/ijms241813997.

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.FASN 抑制通过减少临床前模型中的脂肪变性、炎症和纤维化来靶向 NASH 的多种驱动因素。

Sci Rep. 2022 Sep 19;12(1):15661. doi: 10.1038/s41598-022-19459-z.

Characterization of long-chain fatty acid-linked bile acids: a major conjugation form of 3β-hydroxy bile acids in feces.长链脂肪酸结合胆汁酸的特征：粪便中 3β-羟基胆汁酸的主要结合形式。

J Lipid Res. 2022 Oct;63(10):100275. doi: 10.1016/j.jlr.2022.100275. Epub 2022 Sep 9.

Mechanism and Therapeutic Targets of c-Jun-N-Terminal Kinases Activation in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中c-Jun氨基末端激酶激活的机制及治疗靶点

Biomedicines. 2022 Aug 20;10(8):2035. doi: 10.3390/biomedicines10082035.

Capsaicin regulates lipid metabolism through modulation of bile acid/gut microbiota metabolism in high-fat-fed SD rats.辣椒素通过调节高脂喂养的SD大鼠胆汁酸/肠道微生物群代谢来调控脂质代谢。

Food Nutr Res. 2022 May 26;66. doi: 10.29219/fnr.v66.8289. eCollection 2022.

The potential role of phenolic compounds on modulating gut microbiota in obesity.酚类化合物在调节肥胖人群肠道微生物群方面的潜在作用。

J Food Drug Anal. 2020 Jun 15;28(2):195-205. doi: 10.38212/2224-6614.1054.

Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.普卢利沙星通过与法尼醇 X 受体相互作用并改变微生物组来逆转非酒精性脂肪性肝炎。

Int J Mol Sci. 2022 Feb 8;23(3):1899. doi: 10.3390/ijms23031899.

Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.胆汁酸受体与非酒精性脂肪性肝病的肠-肝轴。

Cells. 2021 Oct 20;10(11):2806. doi: 10.3390/cells10112806.

本文引用的文献

Hepatol Commun. 2017 Oct 16;1(10):1024-1042. doi: 10.1002/hep4.1108. eCollection 2017 Dec.

An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice.肠道法尼醇X受体-神经酰胺信号轴调节小鼠肝脏糖异生

Diabetes. 2017 Mar;66(3):613-626. doi: 10.2337/db16-0663. Epub 2016 Nov 8.

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.奥贝胆酸治疗原发性胆汁性胆管炎的安慰剂对照临床试验。

N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.肠道法尼醇X受体信号传导促进非酒精性脂肪性肝病。

J Clin Invest. 2015 Jan;125(1):386-402. doi: 10.1172/JCI76738. Epub 2014 Dec 15.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.法尼醇X核受体配体奥贝胆酸治疗非肝硬化、非酒精性脂肪性肝炎（FLINT）：一项多中心、随机、安慰剂对照试验

Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7.

Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice.益生菌通过下调 Fxr-Fgf15 轴诱导小鼠肝脏胆汁酸合成。

Cell Rep. 2014 Apr 10;7(1):12-8. doi: 10.1016/j.celrep.2014.02.032. Epub 2014 Mar 20.

Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity.微生物组重塑导致肠道法尼醇 X 受体信号抑制和肥胖减少。

Nat Commun. 2013;4:2384. doi: 10.1038/ncomms3384.

A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents.空腹成纤维细胞生长因子19（FGF19）水平降低与肥胖青少年非酒精性脂肪性肝病的发生有关。

J Pediatr Endocrinol Metab. 2012;25(11-12):1089-93. doi: 10.1515/jpem-2012-0253.

FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.FGF19 作为一种餐后、胰岛素非依赖的肝脏蛋白和糖原合成的激活剂。

Science. 2011 Mar 25;331(6024):1621-4. doi: 10.1126/science.1198363.

The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.FGF19 对肝脏的反应在非酒精性脂肪性肝病和胰岛素抵抗患者中受损。

Am J Physiol Gastrointest Liver Physiol. 2010 Mar;298(3):G440-5. doi: 10.1152/ajpgi.00322.2009. Epub 2010 Jan 21.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验